Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of July 2022, with the report dated July 28, 2022. The document serves as a transaction notification regarding a purchase of company securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of an insider transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of notional ADSs |
| Instrument | American Depositary Shares (ADSs) |
| Price per ADS | $42.2900 |
| Volume | 1,217.974 ADSs |
| Transaction Date | July 22, 2022 |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single transaction within Dr. Barron's GSK Executive Supplemental Savings Plan account.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a routine disclosure of an executive's participation in a savings plan.
Key Facts for Investor Verification
- The transaction was an acquisition of notional ADSs by Dr. H Barron, Chief Scientific Officer and President, R&D.
- The purchase occurred on July 22, 2022, at a price of $42.29 per ADS.
- The transaction was executed via the GSK Executive Supplemental Savings Plan on the NYSE.
- This filing does not contain quarterly or annual financial results.